Pharmacokinetics of oral and compounded intravenous gabapentin in Duroc swine (Sus Scrofa)
The objective of this study was to determine the pharmacokinetics (PK) of oral (OS; 20 mg/kg) and compounded intravenous (IV; 5.5 mg/kg) gabapentin in 6 healthy, adult, Duroc pigs. Subjects were randomized to receive IV and OS gabapentin in a cross‐over design, with at least 14 days of wash‐out peri...
Saved in:
Published in | Journal of veterinary pharmacology and therapeutics Vol. 44; no. 5; pp. 776 - 782 |
---|---|
Main Authors | , , , , , |
Format | Journal Article |
Language | English |
Published |
England
01.09.2021
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | The objective of this study was to determine the pharmacokinetics (PK) of oral (OS; 20 mg/kg) and compounded intravenous (IV; 5.5 mg/kg) gabapentin in 6 healthy, adult, Duroc pigs. Subjects were randomized to receive IV and OS gabapentin in a cross‐over design, with at least 14 days of wash‐out period between the two rounds of drug administrations. Blood samples were obtained before gabapentin administration and at various times up to 24 h, and harvested plasma was stored at −80°C until analysis. Concentration of gabapentin was quantified using a previously validated liquid chromatography/tandem mass spectrometry method, and compartment models were fitted to time‐concentration data using non‐linear mixed effect (population) analysis. A two‐compartment model best fitted the data following IV administration. Typical values for volume of the central compartment and clearance and calculated volume of distribution at steady‐state and terminal half‐life were 170 ml/kg, 1.2 ml/(kg*min), and 594 ml/kg and 360 min, respectively. For the oral route, absorption half‐life, estimated maximal plasma concentration and time to reach maximal plasma concentration were 58 min, 9155 ng/ml, and 194 min, respectively. Estimated oral bioavailability was 47%. Short‐lived sedation (approximately 15 min) with sternal or lateral recumbency after IV administration was observed in all subjects without adverse clinical effects. Simulation based on the results of this study suggests that a first oral gabapentin dose of 15 mg/kg and subsequent doses of 8.5 mg/kg every 8 h would achieve and maintain plasma concentrations between 5 and 8 μg/ml in pigs. |
---|---|
AbstractList | The objective of this study was to determine the pharmacokinetics (PK) of oral (OS; 20 mg/kg) and compounded intravenous (IV; 5.5 mg/kg) gabapentin in 6 healthy, adult, Duroc pigs. Subjects were randomized to receive IV and OS gabapentin in a cross‐over design, with at least 14 days of wash‐out period between the two rounds of drug administrations. Blood samples were obtained before gabapentin administration and at various times up to 24 h, and harvested plasma was stored at −80°C until analysis. Concentration of gabapentin was quantified using a previously validated liquid chromatography/tandem mass spectrometry method, and compartment models were fitted to time‐concentration data using non‐linear mixed effect (population) analysis. A two‐compartment model best fitted the data following IV administration. Typical values for volume of the central compartment and clearance and calculated volume of distribution at steady‐state and terminal half‐life were 170 ml/kg, 1.2 ml/(kg*min), and 594 ml/kg and 360 min, respectively. For the oral route, absorption half‐life, estimated maximal plasma concentration and time to reach maximal plasma concentration were 58 min, 9155 ng/ml, and 194 min, respectively. Estimated oral bioavailability was 47%. Short‐lived sedation (approximately 15 min) with sternal or lateral recumbency after IV administration was observed in all subjects without adverse clinical effects. Simulation based on the results of this study suggests that a first oral gabapentin dose of 15 mg/kg and subsequent doses of 8.5 mg/kg every 8 h would achieve and maintain plasma concentrations between 5 and 8 μg/ml in pigs. The objective of this study was to determine the pharmacokinetics (PK) of oral (OS; 20 mg/kg) and compounded intravenous (IV; 5.5 mg/kg) gabapentin in 6 healthy, adult, Duroc pigs. Subjects were randomized to receive IV and OS gabapentin in a cross-over design, with at least 14 days of wash-out period between the two rounds of drug administrations. Blood samples were obtained before gabapentin administration and at various times up to 24 h, and harvested plasma was stored at -80°C until analysis. Concentration of gabapentin was quantified using a previously validated liquid chromatography/tandem mass spectrometry method, and compartment models were fitted to time-concentration data using non-linear mixed effect (population) analysis. A two-compartment model best fitted the data following IV administration. Typical values for volume of the central compartment and clearance and calculated volume of distribution at steady-state and terminal half-life were 170 ml/kg, 1.2 ml/(kg*min), and 594 ml/kg and 360 min, respectively. For the oral route, absorption half-life, estimated maximal plasma concentration and time to reach maximal plasma concentration were 58 min, 9155 ng/ml, and 194 min, respectively. Estimated oral bioavailability was 47%. Short-lived sedation (approximately 15 min) with sternal or lateral recumbency after IV administration was observed in all subjects without adverse clinical effects. Simulation based on the results of this study suggests that a first oral gabapentin dose of 15 mg/kg and subsequent doses of 8.5 mg/kg every 8 h would achieve and maintain plasma concentrations between 5 and 8 μg/ml in pigs. The objective of this study was to determine the pharmacokinetics (PK) of oral (OS; 20 mg/kg) and compounded intravenous (IV; 5.5 mg/kg) gabapentin in 6 healthy, adult, Duroc pigs. Subjects were randomized to receive IV and OS gabapentin in a cross-over design, with at least 14 days of wash-out period between the two rounds of drug administrations. Blood samples were obtained before gabapentin administration and at various times up to 24 h, and harvested plasma was stored at -80°C until analysis. Concentration of gabapentin was quantified using a previously validated liquid chromatography/tandem mass spectrometry method, and compartment models were fitted to time-concentration data using non-linear mixed effect (population) analysis. A two-compartment model best fitted the data following IV administration. Typical values for volume of the central compartment and clearance and calculated volume of distribution at steady-state and terminal half-life were 170 ml/kg, 1.2 ml/(kg*min), and 594 ml/kg and 360 min, respectively. For the oral route, absorption half-life, estimated maximal plasma concentration and time to reach maximal plasma concentration were 58 min, 9155 ng/ml, and 194 min, respectively. Estimated oral bioavailability was 47%. Short-lived sedation (approximately 15 min) with sternal or lateral recumbency after IV administration was observed in all subjects without adverse clinical effects. Simulation based on the results of this study suggests that a first oral gabapentin dose of 15 mg/kg and subsequent doses of 8.5 mg/kg every 8 h would achieve and maintain plasma concentrations between 5 and 8 μg/ml in pigs.The objective of this study was to determine the pharmacokinetics (PK) of oral (OS; 20 mg/kg) and compounded intravenous (IV; 5.5 mg/kg) gabapentin in 6 healthy, adult, Duroc pigs. Subjects were randomized to receive IV and OS gabapentin in a cross-over design, with at least 14 days of wash-out period between the two rounds of drug administrations. Blood samples were obtained before gabapentin administration and at various times up to 24 h, and harvested plasma was stored at -80°C until analysis. Concentration of gabapentin was quantified using a previously validated liquid chromatography/tandem mass spectrometry method, and compartment models were fitted to time-concentration data using non-linear mixed effect (population) analysis. A two-compartment model best fitted the data following IV administration. Typical values for volume of the central compartment and clearance and calculated volume of distribution at steady-state and terminal half-life were 170 ml/kg, 1.2 ml/(kg*min), and 594 ml/kg and 360 min, respectively. For the oral route, absorption half-life, estimated maximal plasma concentration and time to reach maximal plasma concentration were 58 min, 9155 ng/ml, and 194 min, respectively. Estimated oral bioavailability was 47%. Short-lived sedation (approximately 15 min) with sternal or lateral recumbency after IV administration was observed in all subjects without adverse clinical effects. Simulation based on the results of this study suggests that a first oral gabapentin dose of 15 mg/kg and subsequent doses of 8.5 mg/kg every 8 h would achieve and maintain plasma concentrations between 5 and 8 μg/ml in pigs. The objective of this study was to determine the pharmacokinetics (PK) of oral (OS; 20 mg/kg) and compounded intravenous (IV; 5.5 mg/kg) gabapentin in 6 healthy, adult, Duroc pigs. Subjects were randomized to receive IV and OS gabapentin in a cross‐over design, with at least 14 days of wash‐out period between the two rounds of drug administrations. Blood samples were obtained before gabapentin administration and at various times up to 24 h, and harvested plasma was stored at −80°C until analysis. Concentration of gabapentin was quantified using a previously validated liquid chromatography/tandem mass spectrometry method, and compartment models were fitted to time‐concentration data using non‐linear mixed effect (population) analysis. A two‐compartment model best fitted the data following IV administration. Typical values for volume of the central compartment and clearance and calculated volume of distribution at steady‐state and terminal half‐life were 170 ml/kg, 1.2 ml/(kg*min), and 594 ml/kg and 360 min, respectively. For the oral route, absorption half‐life, estimated maximal plasma concentration and time to reach maximal plasma concentration were 58 min, 9155 ng/ml, and 194 min, respectively. Estimated oral bioavailability was 47%. Short‐lived sedation (approximately 15 min) with sternal or lateral recumbency after IV administration was observed in all subjects without adverse clinical effects. Simulation based on the results of this study suggests that a first oral gabapentin dose of 15 mg/kg and subsequent doses of 8.5 mg/kg every 8 h would achieve and maintain plasma concentrations between 5 and 8 μg/ml in pigs. |
Author | Hampton, Chiara E. Queiroz‐Williams, Patricia Martin, Anna Oubre, Montana J. Gisclair, Andrea T. Pypendop, Bruno H. |
Author_xml | – sequence: 1 givenname: Chiara E. orcidid: 0000-0002-8344-8569 surname: Hampton fullname: Hampton, Chiara E. email: bartolomeocane@gmail.com organization: Louisiana State University – sequence: 2 givenname: Patricia surname: Queiroz‐Williams fullname: Queiroz‐Williams, Patricia organization: Louisiana State University – sequence: 3 givenname: Montana J. surname: Oubre fullname: Oubre, Montana J. organization: Louisiana State University – sequence: 4 givenname: Anna surname: Martin fullname: Martin, Anna organization: Parkville Animal Hospital – sequence: 5 givenname: Andrea T. surname: Gisclair fullname: Gisclair, Andrea T. organization: Louisiana State University – sequence: 6 givenname: Bruno H. orcidid: 0000-0002-0894-0991 surname: Pypendop fullname: Pypendop, Bruno H. organization: University of California Davis |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/33978255$$D View this record in MEDLINE/PubMed |
BookMark | eNqFkU1PHSEYhUmjqVftwj_QsNTFKB_DwF021o82Jppou-iGvAOMxc7AFGY0_nvRe92YNrIh4Tzn5OU922gjxOAQ2qPkkJZzdHc_HlK2lPIDWlDeiIopJTbQgtCaVFIqvoW2c74jhHBF6Ue0xflSKibEAv26-g1pABP_-OAmbzKOHY4JegzBYhOHMc7BOot9mBLcuxDnjG-hhdGFyYfyjL_OKRqcH0oA3r8u8rVJsYODXbTZQZ_dp_W9g36cntwcn1cXl2ffjr9cVIYLJStnmVG8Y5I0hklmiZUEZEu6FrhkDjg0S2WKZjlTLaUgOto6SygriqEt30H7q9wxxb-zy5MefDau7yG4Mq1mDW9UXSvB30cFa6ggdU0L-nmNzu3grB6THyA96tfVFeBoBZTf5pxcp42fYPLxeVG-15To53J0KUe_lFMcB28cr6H_YtfpD753j_8H9fefVyvHEz91nf0 |
CitedBy_id | crossref_primary_10_1111_jvp_13451 crossref_primary_10_1111_jvp_13436 crossref_primary_10_1016_j_vaa_2024_06_006 |
Cites_doi | 10.1016/j.jpain.2015.09.011 10.1097/ACO.0b013e3282effaa7 10.2460/javma.251.10.1175 10.1111/j.1365-2885.2010.01161.x 10.2147/JPR.S172300 10.1016/0309-1740(94)90121-X 10.1016/j.semcdb.2006.09.003 10.2460/ajvr.71.7.817 10.1016/j.jpain.2013.01.768 10.1016/S0149-2918(03)90011-7 10.1016/S0169-328X(01)00188-7 10.1111/jvp.12042 10.1111/j.1365-2885.2012.01384.x 10.1111/j.1365-2885.2004.00617.x 10.1016/S0309-1740(97)00146-0 10.1016/j.tvjl.2009.09.022 10.1016/j.tvjl.2010.08.008 10.1523/JNEUROSCI.21-06-01868.2001 10.1111/jvim.15313 10.1177/1098612X17719399 10.1177/0023677213514044 10.1023/A:1018951214146 10.1111/j.1528-1157.1999.tb00743.x 10.1007/s12272-013-0057-y 10.1111/j.1528-1157.1991.tb04689.x 10.1201/b14095 |
ContentType | Journal Article |
Copyright | 2021 John Wiley & Sons Ltd 2021 John Wiley & Sons Ltd. |
Copyright_xml | – notice: 2021 John Wiley & Sons Ltd – notice: 2021 John Wiley & Sons Ltd. |
DBID | AAYXX CITATION NPM 7X8 7S9 L.6 |
DOI | 10.1111/jvp.12977 |
DatabaseName | CrossRef PubMed MEDLINE - Academic AGRICOLA AGRICOLA - Academic |
DatabaseTitle | CrossRef PubMed MEDLINE - Academic AGRICOLA AGRICOLA - Academic |
DatabaseTitleList | PubMed MEDLINE - Academic CrossRef AGRICOLA |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Veterinary Medicine Pharmacy, Therapeutics, & Pharmacology |
EISSN | 1365-2885 |
EndPage | 782 |
ExternalDocumentID | 33978255 10_1111_jvp_12977 JVP12977 |
Genre | article Journal Article |
GrantInformation_xml | – fundername: Louisiana State University, Veterinary Clinical Sciences |
GroupedDBID | --- .3N .GA .Y3 05W 0R~ 10A 1OB 1OC 29L 31~ 33P 36B 3SF 4.4 50Y 50Z 51W 51X 52M 52N 52O 52P 52S 52T 52U 52W 52X 53G 5GY 5HH 5LA 5VS 66C 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A03 AAESR AAEVG AAHBH AAHHS AAHQN AAMNL AANHP AANLZ AAONW AASGY AAXRX AAYCA AAZKR ABCQN ABCUV ABEML ABJNI ABPVW ACAHQ ACBWZ ACCFJ ACCZN ACFBH ACGFS ACPOU ACRPL ACSCC ACXBN ACXQS ACYXJ ADBBV ADEOM ADIZJ ADKYN ADMGS ADNMO ADOZA ADXAS ADZMN AEEZP AEIGN AEIMD AENEX AEQDE AEUQT AEUYR AFBPY AFEBI AFFPM AFGKR AFPWT AFWVQ AFZJQ AHBTC AHEFC AITYG AIURR AIWBW AJBDE AJXKR ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN ALVPJ AMBMR AMYDB ASPBG ATUGU AUFTA AVWKF AZBYB AZFZN AZVAB BAFTC BDRZF BFHJK BHBCM BMNLL BMXJE BNHUX BROTX BRXPI BY8 C45 CAG COF CS3 D-E D-F DCZOG DPXWK DR2 DRFUL DRSTM DU5 EBS ECGQY EJD ESX EYRJQ F00 F01 F04 F5P FEDTE FZ0 G-S G.N GODZA H.T H.X HF~ HGLYW HVGLF HVLQZ HZI HZ~ IHE IX1 J0M K48 LATKE LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LW6 LYRES MEWTI MK4 MRFUL MRSTM MSFUL MSSTM MXFUL MXSTM N04 N05 NF~ O66 O9- OIG OVD P2P P2W P2X P4D PALCI Q.N Q11 QB0 R.K RIWAO RJQFR ROL RX1 SAMSI SUPJJ TEORI UB1 W8V W99 WBKPD WIH WIK WOHZO WOIKV WPGGZ WQJ WRC WXSBR XG1 ZZTAW ~IA ~KM ~WT AAYXX AEYWJ AGHNM AGQPQ AGYGG CITATION AAMMB AEFGJ AGXDD AIDQK AIDYY NPM 7X8 7S9 L.6 |
ID | FETCH-LOGICAL-c3587-ed2c83f2706c272d0d70a7b0fba372ea3a698c6c2d328b11a5f1bed0123a6c1b3 |
IEDL.DBID | DR2 |
ISSN | 0140-7783 1365-2885 |
IngestDate | Fri Jul 11 18:40:31 EDT 2025 Fri Jul 11 02:59:08 EDT 2025 Mon Jul 21 05:34:34 EDT 2025 Thu Apr 24 23:06:54 EDT 2025 Tue Jul 01 02:03:48 EDT 2025 Wed Jan 22 16:29:10 EST 2025 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 5 |
Keywords | swine pharmacokinetics gabapentin pig |
Language | English |
License | 2021 John Wiley & Sons Ltd. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c3587-ed2c83f2706c272d0d70a7b0fba372ea3a698c6c2d328b11a5f1bed0123a6c1b3 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 ObjectType-Undefined-3 |
ORCID | 0000-0002-0894-0991 0000-0002-8344-8569 |
PMID | 33978255 |
PQID | 2526150441 |
PQPubID | 23479 |
PageCount | 7 |
ParticipantIDs | proquest_miscellaneous_2636844853 proquest_miscellaneous_2526150441 pubmed_primary_33978255 crossref_citationtrail_10_1111_jvp_12977 crossref_primary_10_1111_jvp_12977 wiley_primary_10_1111_jvp_12977_JVP12977 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | September 2021 |
PublicationDateYYYYMMDD | 2021-09-01 |
PublicationDate_xml | – month: 09 year: 2021 text: September 2021 |
PublicationDecade | 2020 |
PublicationPlace | England |
PublicationPlace_xml | – name: England |
PublicationTitle | Journal of veterinary pharmacology and therapeutics |
PublicationTitleAlternate | J Vet Pharmacol Ther |
PublicationYear | 2021 |
References | 1998; 49 2010; 33 2004; 27 1991; 32 1986; 36 2014; 48 1995 2017; 251 1999; 40 2011; 190 1999; 288 2016; 17 2018; 20 2001; 21 2013; 36 2013; 14 17 1995; 23 1993; 10 2003; 25 1994; 38 1982 2007; 20 2018; 11 2018; 32 2001; 95 2011; 187 2010; 71 e_1_2_11_10_1 e_1_2_11_32_1 e_1_2_11_31_1 e_1_2_11_14_1 e_1_2_11_13_1 e_1_2_11_12_1 Vollmer K. O. (e_1_2_11_30_1) 1986; 36 e_1_2_11_11_1 e_1_2_11_7_1 e_1_2_11_29_1 e_1_2_11_28_1 e_1_2_11_5_1 Bradshaw R. H. (e_1_2_11_6_1) 1995 e_1_2_11_27_1 e_1_2_11_4_1 e_1_2_11_26_1 e_1_2_11_3_1 e_1_2_11_2_1 Pan H.‐L. (e_1_2_11_22_1) 1999; 288 e_1_2_11_21_1 e_1_2_11_20_1 Radulovic L. L. (e_1_2_11_24_1) 1995; 23 e_1_2_11_25_1 e_1_2_11_9_1 e_1_2_11_23_1 e_1_2_11_8_1 e_1_2_11_18_1 e_1_2_11_17_1 e_1_2_11_16_1 e_1_2_11_15_1 e_1_2_11_19_1 |
References_xml | – volume: 23 start-page: 441 year: 1995 end-page: 448 article-title: Disposition of gabapentin (neurontin) in mice, rats, dogs, and monkeys publication-title: Drug Metabolism and Disposition – volume: 10 start-page: 276 year: 1993 end-page: 281 article-title: A saturable transport mechanism in the intestinal absorption of gabapentin is the underlying cause of the lack of proportionality between increasing dose and drug levels in plasma publication-title: Pharmaceutical Research – volume: 95 start-page: 1 year: 2001 end-page: 8 article-title: Dorsal root ganglion neurons show increased expression of the calcium channel α2δ‐1 subunit following partial sciatic nerve injury publication-title: Molecular Brain Research – start-page: 29 year: 1995 end-page: 30 article-title: Effects of mixing and duration on the welfare of pigs during transport publication-title: Transport and Lairage Conditions – volume: 36 start-page: 237 year: 2013 end-page: 251 article-title: Implications and mechanism of action of gabapentin in neuropathic pain publication-title: Archives of Pharmacal Research – volume: 251 start-page: 1175 year: 2017 end-page: 1181 article-title: Effects of a single preappointment dose of gabapentin on signs of stress in cats during transportation and veterinary examination publication-title: Journal of the American Veterinary Medical Association – volume: 33 start-page: 485 year: 2010 end-page: 494 article-title: Pharmacokinetic profile and behavioral effects of gabapentin in the horse publication-title: Journal of Veterinary Pharmacology and Therapeutics – volume: 38 start-page: 329 year: 1994 end-page: 340 article-title: Relationships between subjective and objective assessments of stress at slaughter and meat quality in pigs publication-title: Meat Science – volume: 11 start-page: 2279 year: 2018 article-title: Open field and a behavior score in PNT model for neuropathic pain in pigs publication-title: Journal of Pain Research – volume: 32 start-page: 1996 year: 2018 end-page: 2002 article-title: The pharmacokinetics of gabapentin in cats publication-title: Journal of Veterinary Internal Medicine – volume: 17 start-page: 565 issue: 5 end-page: 570 article-title: α2δ and the mechanism of action of gabapentin in the treatment of pain publication-title: Seminars in Cell & Developmental Biology – volume: 20 start-page: 535 year: 2018 end-page: 543 article-title: Use of single‐dose oral gabapentin to attenuate fear responses in cage‐trap confined community cats: a double‐blind, placebo‐controlled field trial publication-title: Journal of Feline Medicine and Surgery – volume: 190 start-page: 98 year: 2011 end-page: 102 article-title: Pharmacokinetics of oral gabapentin alone or co‐administered with meloxicam in ruminant beef calves publication-title: The Veterinary Journal – volume: 27 start-page: 479 year: 2004 end-page: 490 article-title: Pharmacodynamics and pharmacokinetics of nonsteroidal anti‐inflammatory drugs in species of veterinary interest publication-title: Journal of Veterinary Pharmacology and Therapeutics – volume: 40 start-page: 474 year: 1999 end-page: 479 article-title: Effects of age and gender on single‐dose pharmacokinetics of gabapentin publication-title: Epilepsia – volume: 36 start-page: 550 year: 2013 end-page: 561 article-title: The pharmacokinetics and effects of meloxicam, gabapentin, and flunixin in postweaning dairy calves following dehorning with local anesthesia publication-title: Journal of Veterinary Pharmacology and Therapeutics – volume: 36 start-page: 830 year: 1986 article-title: Pharmacokinetics and metabolism of gabapentin in rat, dog and man publication-title: Arzneimittel‐Forschung – year: 1982 – volume: 32 start-page: 539 year: 1991 end-page: 542 article-title: Double‐blind study of gabapentin in the treatment of partial seizures publication-title: Epilepsia – volume: 20 start-page: 456 year: 2007 end-page: 472 article-title: Gabapentin and pregabalin for chronic neuropathic and early postsurgical pain: current evidence and future directions publication-title: Current Opinion in Anesthesiology – volume: 14 start-page: 590 year: 2013 end-page: 603 article-title: A randomized, double‐blind, placebo‐controlled trial to assess the efficacy and safety of gabapentin enacarbil in subjects with neuropathic pain associated with postherpetic neuralgia (PXN110748) publication-title: The Journal of Pain – volume: 17 start-page: 36 year: 2016 end-page: 49 article-title: Peripheral neuritis trauma in pigs: a neuropathic pain model publication-title: The Journal of Pain – volume: 25 start-page: 81 year: 2003 end-page: 104 article-title: Gabapentin dosing for neuropathic pain: evidence from randomized, placebo‐controlled clinical trials publication-title: Clinical Therapeutics – volume: 49 start-page: 257 year: 1998 end-page: 265 article-title: Meat quality in pigs subjected to minimal preslaughter stress publication-title: Meat Science – volume: 36 start-page: 14 year: 2013 end-page: 20 article-title: Pharmacokinetics and milk secretion of gabapentin and meloxicam co‐administered orally in Holstein‐Friesian cows: Milk secretion of gabapentin and meloxicam in dairy cattle publication-title: Journal of Veterinary Pharmacology and Therapeutics – volume: 187 start-page: 133 year: 2011 end-page: 135 article-title: Pharmacokinetics of oral gabapentin in greyhound dogs publication-title: The Veterinary Journal – volume: 48 start-page: 78 year: 2014 end-page: 81 article-title: Development and refinement of a technique for short‐term intravascular auricular vein catheter placement in mature sows publication-title: Laboratory Animals – volume: 71 start-page: 817 year: 2010 end-page: 821 article-title: Pharmacokinetics of gabapentin in cats publication-title: American Journal of Veterinary Research – volume: 21 start-page: 1868 year: 2001 end-page: 1875 article-title: Upregulation of dorsal root ganglion α2δ calcium channel subunit and its correlation with allodynia in spinal nerve‐injured rats publication-title: Journal of Neuroscience – volume: 288 start-page: 1026 year: 1999 end-page: 1030 article-title: Gabapentin suppresses ectopic nerve discharges and reverses allodynia in neuropathic rats publication-title: Journal of Pharmacology and Experimental Therapeutics – ident: e_1_2_11_8_1 doi: 10.1016/j.jpain.2015.09.011 – ident: e_1_2_11_12_1 doi: 10.1097/ACO.0b013e3282effaa7 – ident: e_1_2_11_29_1 doi: 10.2460/javma.251.10.1175 – ident: e_1_2_11_28_1 doi: 10.1111/j.1365-2885.2010.01161.x – ident: e_1_2_11_9_1 doi: 10.2147/JPR.S172300 – ident: e_1_2_11_31_1 doi: 10.1016/0309-1740(94)90121-X – ident: e_1_2_11_19_1 doi: 10.1016/j.semcdb.2006.09.003 – ident: e_1_2_11_25_1 doi: 10.2460/ajvr.71.7.817 – ident: e_1_2_11_32_1 doi: 10.1016/j.jpain.2013.01.768 – ident: e_1_2_11_4_1 doi: 10.1016/S0149-2918(03)90011-7 – ident: e_1_2_11_20_1 doi: 10.1016/S0169-328X(01)00188-7 – ident: e_1_2_11_13_1 doi: 10.1111/jvp.12042 – ident: e_1_2_11_18_1 doi: 10.1111/j.1365-2885.2012.01384.x – ident: e_1_2_11_16_1 doi: 10.1111/j.1365-2885.2004.00617.x – ident: e_1_2_11_7_1 doi: 10.1016/S0309-1740(97)00146-0 – ident: e_1_2_11_14_1 doi: 10.1016/j.tvjl.2009.09.022 – ident: e_1_2_11_10_1 doi: 10.1016/j.tvjl.2010.08.008 – ident: e_1_2_11_17_1 doi: 10.1523/JNEUROSCI.21-06-01868.2001 – ident: e_1_2_11_2_1 doi: 10.1111/jvim.15313 – start-page: 29 year: 1995 ident: e_1_2_11_6_1 article-title: Effects of mixing and duration on the welfare of pigs during transport publication-title: Transport and Lairage Conditions – volume: 23 start-page: 441 year: 1995 ident: e_1_2_11_24_1 article-title: Disposition of gabapentin (neurontin) in mice, rats, dogs, and monkeys publication-title: Drug Metabolism and Disposition – volume: 36 start-page: 830 year: 1986 ident: e_1_2_11_30_1 article-title: Pharmacokinetics and metabolism of gabapentin in rat, dog and man publication-title: Arzneimittel‐Forschung – ident: e_1_2_11_23_1 doi: 10.1177/1098612X17719399 – ident: e_1_2_11_21_1 doi: 10.1177/0023677213514044 – ident: e_1_2_11_27_1 doi: 10.1023/A:1018951214146 – ident: e_1_2_11_5_1 doi: 10.1111/j.1528-1157.1999.tb00743.x – ident: e_1_2_11_15_1 doi: 10.1007/s12272-013-0057-y – ident: e_1_2_11_26_1 doi: 10.1111/j.1528-1157.1991.tb04689.x – ident: e_1_2_11_3_1 – ident: e_1_2_11_11_1 doi: 10.1201/b14095 – volume: 288 start-page: 1026 year: 1999 ident: e_1_2_11_22_1 article-title: Gabapentin suppresses ectopic nerve discharges and reverses allodynia in neuropathic rats publication-title: Journal of Pharmacology and Experimental Therapeutics |
SSID | ssj0003811 |
Score | 2.2942572 |
Snippet | The objective of this study was to determine the pharmacokinetics (PK) of oral (OS; 20 mg/kg) and compounded intravenous (IV; 5.5 mg/kg) gabapentin in 6... The objective of this study was to determine the pharmacokinetics (PK) of oral (OS; 20 mg/kg) and compounded intravenous (IV; 5.5 mg/kg) gabapentin in 6... |
SourceID | proquest pubmed crossref wiley |
SourceType | Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 776 |
SubjectTerms | absorption adults bioavailability cross-over studies drugs Duroc gabapentin half life intravenous injection liquid chromatography pharmacokinetics pig sedation Sus scrofa swine tandem mass spectrometry |
Title | Pharmacokinetics of oral and compounded intravenous gabapentin in Duroc swine (Sus Scrofa) |
URI | https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fjvp.12977 https://www.ncbi.nlm.nih.gov/pubmed/33978255 https://www.proquest.com/docview/2526150441 https://www.proquest.com/docview/2636844853 |
Volume | 44 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Za9wwEB5CnvrSNttre6GWElKIF1uyJIc-lbYhBFKW5iCUgtEZSoqzZI-S_vrOyPZu04vSN9saWbKk8XySZj4BvEDQFrQzPtNK2ay0scpMsWMyR1QxnleF9BQofPBe7R2X-6fydA1e9bEwLT_EcsGNNCP9r0nBjZ3-qOSLyQiNlaZIcvLVIkD0YUUdhZao6N0Xta5ExyqUvHj6nNdt0S8A8zpeTQZn9xZ86qva-pmcj-YzO3LffmJx_M9vuQ03OyDKXrcjZwPWQjOAzXHLZH21zY5WgVnTbbbJxiuO66sBDE7IjSbF8rKDbnv-Dnzshc7xljKyi8iIAoCZxjPyXqdDnIJnn2lJeZHoYdmZsVgOHViBj9nbOVpUNv2KL2Bbh5h8SJbCvLwLx7vvjt7sZd3hDZkTEn9cwXNXich1rhzHbs-9zo22ebRGaB6MMGqncpjmBa9sURgZCxs8QTyjXGHFPVhvLprwAFhemqqMueNF1KX1ykScNProvZNR5jEOYavvxtp1zOZ0wMaXejnDWUzq1L5DeL4UnbR0Hr8TetaPhRqVjXZQTBOwRWouORHoI4T8i4wSqsJJrxRDuN8OpGVRAtEfTskl1jgNhz_Xod4_GaeLh_8u-ghucPK4SR5wj2F9djkPTxAyzezTpBvfAe5SFFM |
linkProvider | Wiley-Blackwell |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3db9MwED-N8QAvGxTYOr4MQtOQliqx4ziTeEHAVMY6VaybJiQU-SOe0FBWsbZo_PXcOUnL-BLiLYnPsWP7cnf23e8AnqHSViqrXaSyzESp8Xmkkx0dWYKKcTxPpKNA4cFB1j9K907kyRK8aGNhanyI-YYbcUb4XxOD04b0j1w-G_dQWil1Da5TRu9gUL1fgEehLEpaB0alctHgCgU_nrbqVWn0i4p5VWMNImd3FT62na09Tc5604np2W8_4Tj-79fcgpVGF2Uv68VzG5bKqgObwxrM-nKbjRaxWRfbbJMNFzDXlx3oHJMnTQjnZYPmhP4OfGiJzvCWKrJzzwgFgOnKMXJgpzxOpWOfaFd5FhBi2ak22A7lrMDH7PUUhSq7-IovYFuHWHxIwkI_vwtHu29Gr_pRk78hskLiv6t03ObCcxVnluPMx07FWpnYGy0UL7XQ2U5uscwJnpsk0dInpnSk5enMJkbcg-XqvCrXgcWpzlMfW554lRqXaY92o_POWell7H0Xttp5LGwDbk45Nj4XcyNnNi7C-Hbh6Zx0XCN6_I7oSbsYCuQ3OkTRVYkjUnDJCUMftci_0GQiy9HulaILa_VKmjclUAFEq1xij8N6-HMfir3jYbjY-HfSx3CjPxrsF_tvD97dh5ucHHCCQ9wDWJ58mZYPUYOamEeBUb4DF6oYbg |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3raxQxEB9qBfGLj_N1PqNIqdA9dpPNo_hJPI9abTnsgyLCkqdIZXvYu5P61zvJ7t5ZX4jfdjeTTTaZ2ZlJZn4BeIpGm5dWu0wKYbLSBJXpYlNnNkLFOKoK7mKi8M6u2Doot4_40Qo873JhGnyIxYJblIz0v44CPnHhRyGfTwaorKS8ABdLkavI0sN3S-woVEVFF78opWItrFAK4-mqnldGv1iY5w3WpHFGV-FD19cm0OR4MJuagf32E4zjf37MNbjSWqLkRcM612HF1z1YGzdQ1mcbZH-ZmXW6QdbIeAlyfdaD3mGMo0nJvGSn3Z-_Ae87omO8jRXJSSARA4Do2pEYvh5PcfKOfIpryvOED0s-aoPtxBMr8DEZzlClktOv-AKyvofFe1FV6Gc34WD0av_lVtae3pBZxvHP5R21igUqc2EpznvuZK6lyYPRTFKvmRabymKZY1SZotA8FMa7aONpYQvDbsFqfVL7O0DyUqsy5JYWQZbGCR3Qa3TBOcsDz0Pow3o3jZVtoc3jCRufq4WLM59UaXz78GRBOmnwPH5H9LjjhQqlLW6h6NrjiFSU04igjzbkX2gEEwq9Xs76cLthpEVTDM0_9Mk59jixw5_7UG0fjtPF3X8nfQSXxsNR9fb17pt7cJnG6JsUDXcfVqdfZv4Bmk9T8zCJyXfh_hcm |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Pharmacokinetics+of+oral+and+compounded+intravenous+gabapentin+in+Duroc+swine+%28Sus+Scrofa%29&rft.jtitle=Journal+of+veterinary+pharmacology+and+therapeutics&rft.au=Hampton%2C+Chiara+E&rft.au=Queiroz-Williams%2C+Patricia&rft.au=Oubre%2C+Montana+J&rft.au=Martin%2C+Anna&rft.date=2021-09-01&rft.issn=1365-2885&rft.eissn=1365-2885&rft.volume=44&rft.issue=5&rft.spage=776&rft_id=info:doi/10.1111%2Fjvp.12977&rft.externalDBID=NO_FULL_TEXT |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0140-7783&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0140-7783&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0140-7783&client=summon |